

## TEXT FIELD DOCUMENTATION WITHIN ABSTRACT

### With COVID-19 abstraction guidance and required text

#### History/Physical:

Date| Age of patient, Sex, Race (must be document if not noted type NS) & Ethnicity if coded other than "0". Info from Physical Exam, Impression, Complaints or Symptoms that relate to the primary site diagnosis. {Document co-morbidity if it affects treatment plan} Text past medical history for sequencing a new primary or if affects cancer diagnosis. {Example: 9/1/2019 58yo WF presents with...} This is the first date seen at your hospital with cancer. PTA scans, xrays, biopsies all go in those labeled text fields; not here.

*TIP: Remember to document negative exam findings as well as positive finding if pertinent to site.*

#### X-ray/scan: (Date all procedures)

Date|X-ray and Scans: Diagnostic and work-up used to R/O metastatic disease Document the location of the tumor, tumor size/extension, involvement of lymph nodes and any extension detail(s) noted in XRs/Scans. Include any PTA scans/results. Do not text info unrelated to the diagnosis or treatment of the primary cancer.

#### Scopes/Manipulative procedures/Diagnostic proc: (Date all procedures)

Date|Scope/laparoscopy: procedures that do not meet 1<sup>st</sup> course surgical guidelines; but provide diagnostic and/or staging info. i.e. FNA; colonoscopy w/bx . Stereotactic needle biopsy, CT guided needle biopsy of liver or lung or other sites. Include results done PTA.

#### Surgery/OP Reports: (Date all procedures)

Date|Name of Procedure: Information and findings related to tumor extension and staging from operative report, i.e. tumor size & location. Include surgeries done PTA. {9/1/2019 Sigmoid colon segmental resection:\_\_\_\_\_}

#### Pathology: (Date all procedures)

Date|Type of tissue: Final DX- final morphology; CAP Summary, Addendums or Revisions {9/1/2019 Sigmoid colon Final Dx: \_\_\_\_\_} Path reports done PTA go here.

#### Labs: (Date all procedures) **Interpretation and date of SARS-CoV-2 viral testing and antibody testing.**

Date|Labs relative to primary site diagnosis, Cytology specimens, Tumor markers, Colon: CEA, KRAS; Breast: Markers, genetics; etc. Most SSDI results go here. {9/1/2019 ER pos 97%, Allred Score 8. PR pos, 80%, Allred score 6. HER2 by IHC 1+ pos. Oncotype DX Score 35} **\*\*See more examples on page 3\*\***

**COVID-19 viral POS 05/09/2020**

**COVID-19 viral NEG 03/09/2020 antibody POS 05/09/2020**

## Staging Text:

Date| Include text of stage and staged by, i.e. {T1N0M0, Stage I by Med Onc}

## REMARKS:

Date of discharge, brief final diagnosis, summary of treatment plan. If last known follow-up date is different from the discharge date note why patient was seen and CA status if known. Any subsequent visits, path reports not related to first course.

### COVID-19 TEXT REQUIREMENTS EXAMPLES:

**U07.1 [date: mm/dd/yyyy]**

**Record treatment in general here. If specific, record in specific treatment fields.**

**FCOT CHG D/T COVID-19 [when first course of treatment changed due to COVID-19]**

**Z75.3 mm/dd/yyyy [When dx, staging, treatment or management delayed because of limited access or postponement due to COVID-19]**

## First Course treatment text fields:

Provide brief description to support code:

**Surgery:** 9/1/2019 R lumpectomy with SLN biopsy and axillary dissection.

**SURG TX delayed D/T COVID-19**

**SURG TX delayed D/T COVID-19 & given as subsequent TX after progression**

**SURG TX delayed & CHG D/T COVID-19**

**SURG TX CHG D/T COVID-19**

**SURG TX DC D/T COVID-19**

**Radiation:** 9/1/2019 EBRT with boost

**EBRT [XRT; RT] DC D/T COVID-19 Or EBRT [XRT; RT] CHG D/T COVID-19**

**EBRT [XRT; RT] delayed D/T COVID-19**

**EBRT [XRT] delayed D/T COVID-19 & given as subsequent TX after progression**

**Radiation other:**

**RT DC D/T COVID-19 or RT CHG D/T COVID-19**

**ICB DC D/T COVID-19 or ICB CHG D/T COVID-19 {ICB = intracavitary brachytherapy}**

**RT delayed d/T COVID-19 or ICB delayed D/T COVID-19**

**RT delayed D/T COVID-19 & given as subsequent TX after progression or**

**ICB delayed D/T COVID-19 & given as subsequent TX after progression**

**Chemotherapy:** 9/1/2019 CHOP

**CHEMO DC D/T COVID-19**

**CHEMO CHG D/T COVID-19**

**CHEMO delayed D/T COVID-19**

**CHEMO delayed D/T COVID-19 & given as subsequent TX after progression**

**Hormone Therapy:** 9/1/2019 Prednisone

**HORMONE DC D/T COVID-19**

**HORMONE CHG D/T COVID-19**

**HORMONE delayed D/T COVID-19**

**HORMONE delayed D/T COVID-19 & given as subsequent TX after progression**

**\*BRM/Immunotherapy:** 9/1/2019 Rituxan

**BRM DC D/T COVID-19 or BMT DC D/T COVID-19**

**BRM CHG D/T COVID-19**

**BRM delayed D/T COVID-19 or BMT delayed D/T COVID-19**

**BRM delayed D/T COVID-19 & given as subsequent TX after progression**

**Hematology Transplant & Endo:** 9/1/2019 Stem Cell Transplant

**Other:** Date|What was done (i.e. herbs and vitamins)

**TIPS**

- *Chronological order if several tests, surgeries, pathology reports.*
- *Avoid using too many abbreviations*
- *Be intentional with text, don't need a story, just facts, brief.*
- *Place text in appropriate text fields.*

**HEMATOPOIETIC MALIGNANCIES:**

Hematopoietic malignancies are abstracted based on a diagnosis made by a physician; either by a pathologist based on a pathology report, hematologist on blood work, the managing physician, or an oncologist. Documentation of lab values in abstract such as RBC, WBC, platelets, etc. is not necessary.

**FOLLOW-UP**

For follow-up purposes, if the registry is not to contact a person because of his/her “mental health status, HIV/AIDS, and/or substance abuse (drugs and alcohol)” put the text in the follow-up area **“DO NOT CONTACT, SPECIAL RELEASE REQUIRED”**.

Use these texting practices along with the detailed COVID-19 Abstraction Guidance document dated 6/2020 located here <https://seer.cancer.gov/tools/covid-19/index.html> Begin with 1/1/2020 dx cases.

**\*Please note change of location for BMT/SCT and place in the text field for BRM even though the codes are with the hormone text field.**

Revised 6/25/2020 **\*COVID-19**